司美格鲁肽注射液的多属性临床综合评价  

Multi-Aattribute Clinical Comprehensive Evaluation of Smegglutide Injection

作　　者：马雅斌 陈丹霞[1] 鲍思蔚[1] 范秀丛 赵月芬 MA Yabin;CHEN Danxia;BAO Siwei;FAN Xiucong;ZHAO Yuefen(Dept.of Pharmacy,Dongfang Hospital,Tongji University,Shanghai 200120,China;Dept.of Pharmacy,Traditional Chinese Medicine Hospital of Changji Hui Autonomous Prefecture,Xinjiang Changji 831100,China)

机构地区：[1]同济大学附属东方医院药学部,上海200120 [2]昌吉回族自治州中医医院药剂科,新疆昌吉831100

出　　处：《中国医院用药评价与分析》2025年第2期215-219,222,共6页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：上海市药学会基金项目(No.SHYXH-ZP-2021-013)。

摘　　要：目的:对司美格鲁肽注射液进行多属性临床综合评价,为医疗机构遴选该药提供参考。方法:遵循《药品临床综合评价管理指南(2021年版试行)》相关规定,参考《中国医疗机构药品评价与遴选快速指南(第二版)》推荐的评价体系、检索策略以及药品评价与遴选的维度、要素、权重等,评价司美格鲁肽注射液的药学特性、有效性、安全性、经济性及其他属性。结果:司美格鲁肽注射液总得分为68.05分,其中药学特性得分为23分,有效性得分为23分,安全性得分为13分,经济性得分为3.55分,其他属性得分为5.5分。评价结果显示,司美格鲁肽的安全性及有效性较好;在经济性方面,由于该药上市时间短,单价较高,经济性需要改善;其他属性方面,该药为医保乙类药品、有保销条件,且不是国家基本药物,会在一定程度上影响其临床应用。结论:司美格鲁肽多属性评分为68.05分,在安全性、经济性及其他属性方面可以进行改善,使之成为临床强推荐药品。OBJECTIVE:To perform the multi-attribute clinical comprehensive evaluation of semaglutide injection,so as to provide reference for the selection of the drug in medical institutions.METHODS:Base on the Guidelines for the Management of Clinical Comprehensive Evaluation of Drugs(Trial Version 2021)and referring to the evaluation system,retrieval strategies,dimensions,elements,weights of drug evaluation and selection recommended in the the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions(the Second Edition),the pharmaceutical characteristics,efficacy,safety,economy,and other attributes of semaglutide injection were evaluated.RESULTS:The total score of semaglutide injection was 68.05 points,including 23 points for pharmaceutical characteristics,23 points for efficacy score,13 points for safety score,3.55 points for economy score,and 5.5 points for other attribute score.The evaluation results showed that semaglutide had good safety and efficacy.In terms of economy,due to the short market time and high unit price,the economy needed to be improved.In terms of other attributes,semaglutide was the class B medical insurance drug with guaranteed sales conditions and was not the national essential drug,which could affect the clinical application.CONCLUSIONS:The multi-attribute score of semaglutide was 68.05 points,which can be improved to be strong clinical recommendation in terms of safety,economy and other attributes.

关 键 词：司美格鲁肽 胰高血糖素样肽-1 药品评价 药品遴选 

分 类 号：R977.15[医药卫生—药品]